NCT03826771: POWER-D

Post-Stroke Optimization of Walking Using Explosive Resistance

Completed Phase 2 Results posted Last updated 24 April 2025

What this trial tests

Phase 2 trial testing Power training in Stroke in 48 participants. Completed in 12 May 2024.

Timeline

6 February 2019

Primary endpoint
15 March 2024

12 May 2024

Quick facts

Lead sponsor	Medical University of South Carolina
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	48
Start date	6 February 2019
Primary completion	15 March 2024
Estimated completion	12 May 2024
Sites	1 location across United States

Drugs / interventions tested

• Power training
• Stretching

Conditions studied

• Stroke — all drugs for Stroke →
• Depression — all drugs for Depression →

Sponsor

Medical University of South Carolina

Who can join

Adults 50 to 70, any sex, with Stroke or Depression. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Change in Mean Score of Depression as Assessed by the Hamilton Rating Scale for Depression Primary · Visit 1 through visit 24 (up to 12 weeks)

The HAM-D is a clinician-rated scale with scores based on clinical interview and family report. It addresses both somatic and psychological symptoms of depression. Items are rated on either a 5-point scale (0 to 4) or 3-point scale (0 to 2), where higher scores represent increasing severity of depression. The scores of the 17 items are summed to obtain a total score (minimum score: 0, maximum score: 52).

Group	Value	95% CI
POWER Training - Depressed	5.20	± 4.31
Stretching	2.17	± 4.72
POWER Training - Non-Depressed	0.14	± 2.83

Change in Self Selected Walking Speed Secondary · Visit 1 through visit 24 (up to 12 weeks)

Subjects will walk on a 14-ft. long gait mat (GaitRite) to measure self-selected and fastest comfortable walking speed and other spatiotemporal parameters of walking. Subjects will be permitted a practice trial, and then be asked to complete three trials at each speed. For all trials, subjects will wear their own shoes and be asked to walk without an assistive device or ankle-foot orthosis.

Group	Value	95% CI
POWER Training - Depressed	0.08	± 0.02
Stretching	0.06	± 0.02
POWER Training - Non-Depressed	0.21	± 0.06

Adverse events — posted to ClinicalTrials.gov

Time frame: throughout the 12 week training intervention. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

POWER Training - Depressed

Serious: 0/19 (0%)

Deaths: 0/19

Stretching

Serious: 0/12 (0%)

Deaths: 0/12

POWER Training - Non-Depressed

Serious: 0/17 (0%)

Deaths: 0/17

Other adverse events (1 terms — click to expand)

Reaction	System	POWER Training - Depressed	Stretching	POWER Training - Non-Depre…
mild injury (sprain/contusion)	Musculoskeletal and connective tissue disorders	—	—	—

Data from ClinicalTrials.gov NCT03826771 adverse events section.

Sponsor's own description

The investigators will study the effects of a 12 week strength training program on individuals who have had a stroke and are depressed to see if this type of exercise training helps treat depression and improves walking function. Our goal is to use the information collected in this study to help design treatments for people who have had a stroke that will help with many of the common consequences of stroke, including depression, muscle weakness and slow walking. Progress toward overcoming some of these issues would be incredibly valuable to any person who has had a stroke and their families.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.